Coherus Oncology Inc [CHRS] stock is trading at $0.85, up 2.94%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CHRS shares have gain 11.54% over the last week, with a monthly amount drifted -13.90%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Coherus Oncology Inc [NASDAQ: CHRS] stock has seen the most recent analyst activity on August 16, 2024, when UBS downgraded its rating to a Neutral and also revised its price target to $1.50 from $4. Previously, Robert W. Baird started tracking the stock with Outperform rating on November 17, 2023, and set its price target to $11. On November 08, 2023, downgrade downgraded it’s rating to Hold. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $12 on July 24, 2023. Truist initiated its recommendation with a Buy and recommended $24 as its price target on May 01, 2023. UBS upgraded its rating to Buy for this stock on March 28, 2023, but kept the price target unchanged to $11. In a note dated June 14, 2022, UBS initiated an Neutral rating and provided a target price of $7 on this stock.
Coherus Oncology Inc [CHRS] stock has fluctuated between $0.66 and $2.43 over the past year. Currently, Wall Street analysts expect the stock to reach $1.05 within the next 12 months. Coherus Oncology Inc [NASDAQ: CHRS] shares were valued at $0.85 at the most recent close of the market. An investor can expect a potential return of 23.53% based on the average CHRS price forecast.
Analyzing the CHRS fundamentals
Coherus Oncology Inc [NASDAQ:CHRS] reported sales of 197.50M for the trailing twelve months, which represents a drop of -90.14%. Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at -0.58%, Pretax Profit Margin comes in at -0.62%, and Net Profit Margin reading is -0.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is 1.07 and Total Capital is -0.99. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8239 points at the first support level, and at 0.7935 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8924, and for the 2nd resistance point, it is at 0.9305.
Ratios To Look Out For
For context, Coherus Oncology Inc’s Current Ratio is 1.22. Also, the Quick Ratio is 1.20, while the Cash Ratio stands at 0.32. Considering the valuation of this stock, the price to sales ratio is 0.50.
Transactions by insiders
Recent insider trading involved Wahlstrom Mats, Director, that happened on May 23 ’25 when 99988.0 shares were sold.
